Suppr超能文献

在血液系统癌症中 PI3 激酶信号通路:miRNA 作用一瞥。

PI3 kinase signaling pathway in hematopoietic cancers: A glance in miRNA's role.

机构信息

Hematopoietic Stem Cell Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

出版信息

J Clin Lab Anal. 2021 Apr;35(4):e23725. doi: 10.1002/jcla.23725. Epub 2021 Mar 5.

Abstract

Hematopoietic cancers are among the most common malignancies worldwide, which are divided into different types depending on the origin of tumor cells. In recent years, the pivotal role of different signaling pathways in the onset and progression of these cancer types has been well established. One of these pathways, whose role in blood malignancies has been well-defined, is PI3K/mTOR/AKT axis. The signaling pathway involves in a wide variety of important biological events in cells. It is clear that dysregulation of mediators involved in PI3 kinase signaling takes a pivotal role in cancer development. Considering the undeniable role of miRNAs, as one of the well-known families of non-coding RNAs, in gene regulation, we aimed to review the role of miRNAs in regulation of PI3 kinase signaling effectors in hematopoietic cancers.

摘要

造血系统恶性肿瘤是全球最常见的恶性肿瘤之一,根据肿瘤细胞起源的不同,可分为不同类型。近年来,不同信号通路在这些癌症类型的发生和进展中的关键作用已得到充分证实。其中一个通路,即 PI3K/mTOR/AKT 轴,其在血液恶性肿瘤中的作用已得到充分定义。该信号通路涉及细胞内的多种重要生物学事件。很明显,参与 PI3 激酶信号的介质失调在癌症的发生中起着关键作用。鉴于 miRNA 作为已知的非编码 RNA 家族之一,在基因调控中具有不可否认的作用,我们旨在综述 miRNA 在调节造血系统恶性肿瘤中 PI3 激酶信号效应物中的作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9060/8059748/fa2e498704f1/JCLA-35-e23725-g002.jpg

相似文献

1
PI3 kinase signaling pathway in hematopoietic cancers: A glance in miRNA's role.
J Clin Lab Anal. 2021 Apr;35(4):e23725. doi: 10.1002/jcla.23725. Epub 2021 Mar 5.
2
Small molecules with huge impacts: the role of miRNA-regulated PI3K pathway in human malignancies.
Mol Biol Rep. 2021 Dec;48(12):8045-8059. doi: 10.1007/s11033-021-06739-6. Epub 2021 Oct 23.
3
Regulation and importance of the PI3K/Akt/mTOR signaling pathway in hematologic malignancies.
Anticancer Agents Med Chem. 2009 Nov;9(9):1024-38. doi: 10.2174/187152009789377772.
4
MicroRNA-99b suppresses human cervical cancer cell activity by inhibiting the PI3K/AKT/mTOR signaling pathway.
J Cell Physiol. 2019 Jun;234(6):9577-9591. doi: 10.1002/jcp.27645. Epub 2018 Nov 27.
5
The role of microRNAs involved in PI3-kinase signaling pathway in colorectal cancer.
J Cell Physiol. 2019 May;234(5):5664-5673. doi: 10.1002/jcp.27415. Epub 2018 Nov 29.
7
Long noncoding RNA SNHG7-miRNA-mRNA axes crosstalk with oncogenic signaling pathways in human cancers.
Chem Biol Drug Des. 2023 May;101(5):1151-1161. doi: 10.1111/cbdd.14118. Epub 2022 Aug 22.
9
Cross-talk between non-coding RNAs and PI3K/AKT/mTOR pathway in colorectal cancer.
Mol Biol Rep. 2021 May;48(5):4797-4811. doi: 10.1007/s11033-021-06458-y. Epub 2021 May 31.
10
MicroRNAs and the PTEN/PI3K/Akt pathway in gastric cancer (Review).
Oncol Rep. 2019 Mar;41(3):1439-1454. doi: 10.3892/or.2019.6962. Epub 2019 Jan 10.

引用本文的文献

1
Engineered immune cell therapies for solid tumors: pharmacological advances, clinical outcomes, and future directions.
Front Pharmacol. 2025 Jun 12;16:1614325. doi: 10.3389/fphar.2025.1614325. eCollection 2025.
2
The Importance of Phosphoinositide 3-Kinase in Neuroinflammation.
Int J Mol Sci. 2024 Oct 30;25(21):11638. doi: 10.3390/ijms252111638.
3
The Progress and Prospects of Immune Cell Therapy for the Treatment of Cancer.
Cell Transplant. 2024 Jan-Dec;33:9636897241231892. doi: 10.1177/09636897241231892.
5
Tumor-infiltrating lymphocytes for treatment of solid tumors: It takes two to tango?
Front Immunol. 2022 Oct 28;13:1018962. doi: 10.3389/fimmu.2022.1018962. eCollection 2022.
7
Micro-RNAs in Human Placenta: Tiny Molecules, Immense Power.
Molecules. 2022 Sep 13;27(18):5943. doi: 10.3390/molecules27185943.
8
Chemotherapy reinforces anti-tumor immune response and enhances clinical efficacy of immune checkpoint inhibitors.
Front Oncol. 2022 Aug 8;12:939249. doi: 10.3389/fonc.2022.939249. eCollection 2022.
9
Personalized Immunotherapy in Colorectal Cancers: Where Do We Stand?
Front Oncol. 2021 Nov 23;11:769305. doi: 10.3389/fonc.2021.769305. eCollection 2021.

本文引用的文献

1
mTOR-targeted cancer therapy: great target but disappointing clinical outcomes, why?
Front Med. 2021 Apr;15(2):221-231. doi: 10.1007/s11684-020-0812-7. Epub 2020 Nov 9.
3
Oncological Emergencies from Pathophysiology and Diagnosis to Treatment: A Narrative Review.
Soc Work Public Health. 2020 Oct 1;35(8):689-709. doi: 10.1080/19371918.2020.1824844. Epub 2020 Sep 24.
5
Strategies to Modulate MicroRNA Functions for the Treatment of Cancer or Organ Injury.
Pharmacol Rev. 2020 Jul;72(3):639-667. doi: 10.1124/pr.119.019026.
6
Immune checkpoints in hematologic malignancies: What made the immune cells and clinicians exhausted!
J Cell Physiol. 2020 Dec;235(12):9080-9097. doi: 10.1002/jcp.29769. Epub 2020 May 7.
7
Role of PI3K/AKT pathway in cancer: the framework of malignant behavior.
Mol Biol Rep. 2020 Jun;47(6):4587-4629. doi: 10.1007/s11033-020-05435-1. Epub 2020 Apr 24.
8
A high-content RNAi screen reveals multiple roles for long noncoding RNAs in cell division.
Nat Commun. 2020 Apr 15;11(1):1851. doi: 10.1038/s41467-020-14978-7.
10
HSP90 and Co-chaperones: Impact on Tumor Progression and Prospects for Molecular-Targeted Cancer Therapy.
Cancer Invest. 2020 May;38(5):310-328. doi: 10.1080/07357907.2020.1752227. Epub 2020 Apr 27.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验